RXDX Overview
Upcoming Projects (RXDX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (RXDX)
-
Discussing new therapies in development for Ulcerative Colitis with a focus on MORF-057 from Morphic and PRA023 from Prometheus
Tickers: MORF, RXDX
Executed On: Jan 23, 2023 at 11:00 AM EST -
2nd look - Discussing the phase 2 results of the ARTEMIS-UC trial, and the potential of PRA023 (anti-TL1A) for the treatment of ulcerative colitis
Ticker: RXDX
Executed On: Dec 12, 2022 at 09:30 AM EST -
Discussing the phase 2 results of the ARTEMIS-UC trial, and the potential of PRA023 (anti-TL1A) for the treatment of ulcerative colitis
Ticker: RXDX
Executed On: Dec 09, 2022 at 02:30 PM EST
Expired Projects (RXDX)
-
Investigating Loxo’s larotrectinib in treating TRK cancers with upcoming data in Q4
Tickers: LOXO, EXEL, RXDX, NVS
Execute By: Dec 12, 2017
Upcoming & Overdue Catalysts (RXDX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (RXDX)
-
Ignyta (RXDX) Presents Phase 1 Data Evaluating Entrectinib in Patients with TRK-, ROS1- or ALK-Positive Solid Tumors
Ticker: RXDX
Occurred on: Feb 09, 2017
Strategic Initiatives (RXDX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
